Cargando…

Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland

The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapica-Topczewska, Katarzyna, Collin, François, Tarasiuk, Joanna, Czarnowska, Agata, Chorąży, Monika, Mirończuk, Anna, Kochanowicz, Jan, Kułakowska, Alina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923173/
https://www.ncbi.nlm.nih.gov/pubmed/33669799
http://dx.doi.org/10.3390/jcm10040868
_version_ 1783658853374623744
author Kapica-Topczewska, Katarzyna
Collin, François
Tarasiuk, Joanna
Czarnowska, Agata
Chorąży, Monika
Mirończuk, Anna
Kochanowicz, Jan
Kułakowska, Alina
author_facet Kapica-Topczewska, Katarzyna
Collin, François
Tarasiuk, Joanna
Czarnowska, Agata
Chorąży, Monika
Mirończuk, Anna
Kochanowicz, Jan
Kułakowska, Alina
author_sort Kapica-Topczewska, Katarzyna
collection PubMed
description The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (p < 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; p < 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity.
format Online
Article
Text
id pubmed-7923173
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79231732021-03-03 Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland Kapica-Topczewska, Katarzyna Collin, François Tarasiuk, Joanna Czarnowska, Agata Chorąży, Monika Mirończuk, Anna Kochanowicz, Jan Kułakowska, Alina J Clin Med Article The aim of the study was to verify the association of clinical relapses and brain activity with disability progression in relapsing/remitting multiple sclerosis patients receiving disease-modifying treatments in Poland. Disability progression was defined as relapse-associated worsening (RAW), progression independent of relapse activity (PIRA), and progression independent of relapses and brain MRI Activity (PIRMA). Data from the Therapeutic Program Monitoring System were analyzed. Three panels of patients were identified: R0, no relapse during treatment, and R1 and R2 with the occurrence of relapse during the first and the second year of treatment, respectively. In the R0 panel, we detected 4.6% PIRA patients at 24 months (p < 0.001, 5.0% at 36 months, 5.6% at 48 months, 6.1% at 60 months). When restricting this panel to patients without brain MRI activity, we detected 3.0% PIRMA patients at 12 months, 4.5% at 24 months, and varying from 5.3% to 6.2% between 36 and 60 months of treatment, respectively. In the R1 panel, RAW was detected in 15.6% patients at 12 months and, in the absence of further relapses, 9.7% at 24 months and 6.8% at 36 months of treatment. The R2 group was associated with RAW significantly more frequently at 24 months compared to the R1 at 12 months (20.7%; p < 0.05), but without a statistical difference later on. In our work, we confirmed that disability progression was independent of relapses and brain MRI activity. MDPI 2021-02-19 /pmc/articles/PMC7923173/ /pubmed/33669799 http://dx.doi.org/10.3390/jcm10040868 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kapica-Topczewska, Katarzyna
Collin, François
Tarasiuk, Joanna
Czarnowska, Agata
Chorąży, Monika
Mirończuk, Anna
Kochanowicz, Jan
Kułakowska, Alina
Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title_full Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title_fullStr Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title_full_unstemmed Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title_short Assessment of Disability Progression Independent of Relapse and Brain MRI Activity in Patients with Multiple Sclerosis in Poland
title_sort assessment of disability progression independent of relapse and brain mri activity in patients with multiple sclerosis in poland
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923173/
https://www.ncbi.nlm.nih.gov/pubmed/33669799
http://dx.doi.org/10.3390/jcm10040868
work_keys_str_mv AT kapicatopczewskakatarzyna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT collinfrancois assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT tarasiukjoanna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT czarnowskaagata assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT chorazymonika assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT mironczukanna assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT kochanowiczjan assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland
AT kułakowskaalina assessmentofdisabilityprogressionindependentofrelapseandbrainmriactivityinpatientswithmultiplesclerosisinpoland